JP2017534645A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017534645A5 JP2017534645A5 JP2017525016A JP2017525016A JP2017534645A5 JP 2017534645 A5 JP2017534645 A5 JP 2017534645A5 JP 2017525016 A JP2017525016 A JP 2017525016A JP 2017525016 A JP2017525016 A JP 2017525016A JP 2017534645 A5 JP2017534645 A5 JP 2017534645A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14192519 | 2014-11-10 | ||
| EP14192519.8 | 2014-11-10 | ||
| PCT/EP2015/075877 WO2016075036A1 (en) | 2014-11-10 | 2015-11-06 | Anti-pdgf-b antibodies and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017534645A JP2017534645A (ja) | 2017-11-24 |
| JP2017534645A5 true JP2017534645A5 (enExample) | 2018-12-06 |
| JP6946184B2 JP6946184B2 (ja) | 2021-10-06 |
Family
ID=51947140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525016A Expired - Fee Related JP6946184B2 (ja) | 2014-11-10 | 2015-11-06 | 抗ｐｄｇｆ−ｂ抗体及び使用法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10087246B2 (enExample) |
| EP (1) | EP3218400A1 (enExample) |
| JP (1) | JP6946184B2 (enExample) |
| KR (1) | KR20170082520A (enExample) |
| CN (1) | CN107148429B (enExample) |
| AR (1) | AR102593A1 (enExample) |
| AU (1) | AU2015345322A1 (enExample) |
| BR (1) | BR112017009792A2 (enExample) |
| CA (1) | CA2963723A1 (enExample) |
| IL (1) | IL251286A0 (enExample) |
| MX (1) | MX2017005975A (enExample) |
| RU (1) | RU2017120361A (enExample) |
| SG (1) | SG11201703426PA (enExample) |
| TW (1) | TW201630934A (enExample) |
| WO (1) | WO2016075036A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2417156E (pt) | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Anticorpos trivalentes, biespecíficos |
| WO2016075035A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | Anti-ang2 antibodies and methods of use |
| JP2017537896A (ja) | 2014-11-10 | 2017-12-21 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 二重特異性抗体及び眼科に使用する方法 |
| SG11201702550WA (en) | 2014-11-10 | 2017-04-27 | Hoffmann La Roche | ANTI-IL-1beta ANTIBODIES AND METHODS OF USE |
| WO2016087416A1 (en) | 2014-12-03 | 2016-06-09 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
| RU2749674C2 (ru) * | 2015-07-29 | 2021-06-16 | Аллерган, Инк. | Антитела против ang-2, содержащие только тяжелую цепь |
| JP2022530442A (ja) * | 2019-04-24 | 2022-06-29 | マジェンタ セラピューティクス インコーポレイテッド | アントラサイクリン抗体薬物複合体およびその使用 |
| JP7674383B2 (ja) | 2020-03-30 | 2025-05-09 | エフ． ホフマン－ラ ロシュ アーゲー | Ｖｅｇｆ及びｐｄｇｆ－ｂに結合する抗体及び使用方法 |
| JP7894873B2 (ja) | 2021-01-25 | 2026-07-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｐｄｇｆ－ｂ抗体及び肺動脈高血圧症（ｐａｈ）を治療するための使用方法 |
| AR134862A1 (es) * | 2024-01-08 | 2026-04-29 | Chugai Pharmaceutical Co Ltd | Moléculas de unión a antígeno que se unen a pdgf-b y pdgf-d, y métodos de uso |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935343A (en) | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
| JP4538461B2 (ja) | 2003-01-24 | 2010-09-08 | アプライド モレキュラー エボリューション，インコーポレイテッド | ヒトＩＬ−１βアンタゴニスト |
| NZ592039A (en) * | 2003-08-27 | 2013-03-28 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
| US20050282233A1 (en) * | 2004-03-05 | 2005-12-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for VEGF/PDGF family of growth factors |
| DE102004062361A1 (de) * | 2004-12-10 | 2006-06-22 | Cocreate Software Gmbh & Co. Kg | Verfahren zur Ableitung von technischen Zeichungen aus 3D Modellen mit mindestens zwei kollidierenden 3D Körpern |
| ZA200705695B (en) * | 2004-12-21 | 2009-02-25 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| SG11201408196RA (en) | 2012-06-28 | 2015-03-30 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| SI3495387T1 (sl) * | 2012-07-13 | 2021-12-31 | Roche Glycart Ag | Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil |
| AU2013342275B2 (en) * | 2012-11-08 | 2017-11-09 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
| RU2015115956A (ru) * | 2012-11-09 | 2017-01-10 | Пфайзер Инк. | Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения |
| JO3405B1 (ar) * | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| CA2904806C (en) | 2013-04-29 | 2021-11-23 | F. Hoffmann-La Roche Ag | Human fcrn-binding modified antibodies and methods of use |
| CN110903398B (zh) | 2014-01-15 | 2023-08-15 | 豪夫迈·罗氏有限公司 | 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体 |
| WO2016075035A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | Anti-ang2 antibodies and methods of use |
| JP2017537896A (ja) | 2014-11-10 | 2017-12-21 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 二重特異性抗体及び眼科に使用する方法 |
| SG11201702550WA (en) | 2014-11-10 | 2017-04-27 | Hoffmann La Roche | ANTI-IL-1beta ANTIBODIES AND METHODS OF USE |
-
2015
- 2015-11-06 EP EP15791586.9A patent/EP3218400A1/en not_active Ceased
- 2015-11-06 CA CA2963723A patent/CA2963723A1/en not_active Abandoned
- 2015-11-06 BR BR112017009792A patent/BR112017009792A2/pt not_active Application Discontinuation
- 2015-11-06 AU AU2015345322A patent/AU2015345322A1/en not_active Abandoned
- 2015-11-06 MX MX2017005975A patent/MX2017005975A/es unknown
- 2015-11-06 KR KR1020177011693A patent/KR20170082520A/ko not_active Withdrawn
- 2015-11-06 RU RU2017120361A patent/RU2017120361A/ru not_active Application Discontinuation
- 2015-11-06 JP JP2017525016A patent/JP6946184B2/ja not_active Expired - Fee Related
- 2015-11-06 CN CN201580058634.5A patent/CN107148429B/zh not_active Expired - Fee Related
- 2015-11-06 SG SG11201703426PA patent/SG11201703426PA/en unknown
- 2015-11-06 WO PCT/EP2015/075877 patent/WO2016075036A1/en not_active Ceased
- 2015-11-09 AR ARP150103646A patent/AR102593A1/es unknown
- 2015-11-09 TW TW104136908A patent/TW201630934A/zh unknown
-
2017
- 2017-03-20 IL IL251286A patent/IL251286A0/en unknown
- 2017-05-09 US US15/590,172 patent/US10087246B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017534646A5 (enExample) | ||
| JP2020062036A5 (enExample) | ||
| JP2017534644A5 (enExample) | ||
| JP2017537896A5 (enExample) | ||
| RU2017120360A (ru) | Биспецифические антитела и способы их применения в офтальмологии | |
| JP2021525087A5 (enExample) | ||
| JP2019501883A5 (enExample) | ||
| RU2017120358A (ru) | Анти-il-1-бета антитела и способы их применения | |
| HRP20211528T1 (hr) | Trispecifični i/ili trovalentni vezujući proteini za prevenciju ili liječenje hiv infekcije | |
| JP2020511947A5 (enExample) | ||
| HRP20191584T1 (hr) | Anti-cd79b protutijela i načini uporabe | |
| RU2017120361A (ru) | Антитела к pdgf-b и способы их применения | |
| JP2020500538A5 (enExample) | ||
| JP2018537966A5 (enExample) | ||
| JP2014511179A5 (enExample) | ||
| RU2020124153A (ru) | Гуманизированные антитела к cd19 человека и способы их применения | |
| JP2019536806A5 (enExample) | ||
| JP2016512551A5 (enExample) | ||
| HRP20200384T1 (hr) | Humanizirana anti-tau(ps422) protutijela i načini uporabe | |
| JP2017504566A5 (enExample) | ||
| RU2018119014A (ru) | АНТИТЕЛА ПРОТИВ Нtr1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2011046732A5 (enExample) | ||
| JP2017528476A5 (enExample) | ||
| FI3484915T3 (fi) | Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä | |
| JP2015533795A5 (enExample) |